Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
NCT04932941 is registered in ClinicalTrials.gov with MetrioPharm AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
- Lead sponsor
- MetrioPharm AG
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 19, 2021
- Completion date
- September 5, 2022
- Enrollment
- 132 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.